Literature DB >> 18803350

"Rescue" regimens after Helicobacter pylori treatment failure.

Javier P Gisbert1.   

Abstract

Helicobacter pylori (H pylori) infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in my opinion, the ideal regimen to treat this infection is still to be found. Currently, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a "rescue" treatment depends on which treatment is used initially. If a clarithromycin-based regimen was used initially, a subsequent metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third "rescue" option. Alternatively, it has recently been suggested that levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, a quadruple regimen may be reserved as a third-line rescue option. Finally, rifabutin-based rescue therapy constitutes an encouraging empirical fourth-line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H pylori eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given. Therefore, the attitude in H pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803350      PMCID: PMC2744171          DOI: 10.3748/wjg.14.5385

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  186 in total

1.  In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

Authors:  J K Akada; M Shirai; K Fujii; K Okita; T Nakazawa
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  [The attitude in a failure to eradicate Helicobacter pylori: surrender or fight?].

Authors:  J P Gisbert
Journal:  Med Clin (Barc)       Date:  1998-12-12       Impact factor: 1.725

3.  Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology.

Authors:  C W Howden; R H Hunt
Journal:  Am J Gastroenterol       Date:  1998-12       Impact factor: 10.864

4.  Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

Authors:  J M Lee; N P Breslin; D K Hyde; M J Buckley; C A O'Morain
Journal:  Aliment Pharmacol Ther       Date:  1999-04       Impact factor: 8.171

Review 5.  Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection.

Authors:  S K Lam; N J Talley
Journal:  J Gastroenterol Hepatol       Date:  1998-01       Impact factor: 4.029

6.  Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States.

Authors:  N Vakil; B Hahn; D McSorley
Journal:  Am J Gastroenterol       Date:  1998-09       Impact factor: 10.864

Review 7.  Eradication of Helicobacter pylori: why does it fail?

Authors:  M Deltenre; R Ntounda; C Jonas; E De Koster
Journal:  Ital J Gastroenterol Hepatol       Date:  1998-10

8.  Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus.

Authors:  A Gasbarrini; V Ojetti; D Pitocco; A Armuzzi; N G Silveri; P Pola; G Ghirlanda; G Gasbarrini
Journal:  Scand J Gastroenterol       Date:  2000-03       Impact factor: 2.423

9.  Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials.

Authors:  L Laine; L Suchower; J Frantz; A Connors; G Neil
Journal:  Am J Gastroenterol       Date:  1998-11       Impact factor: 10.864

10.  Strategy for the retreatment of failed Helicobacter pylori eradication therapy: a case series.

Authors:  G Battaglia; F Di Mario; S Vigneri; F Vianello; M E Benvenuti; P M Donisi; V Stracca-Pansa; M Pasquino
Journal:  Ital J Gastroenterol Hepatol       Date:  1998-08
View more
  32 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

2.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Authors:  Yuqin Li; Xiayue Huang; Linhua Yao; Ruihua Shi; Guoxin Zhang
Journal:  Wien Klin Wochenschr       Date:  2010-07-16       Impact factor: 1.704

Review 3.  Microbial biofilms and gastrointestinal diseases.

Authors:  Erik C von Rosenvinge; Graeme A O'May; Sandra Macfarlane; George T Macfarlane; Mark E Shirtliff
Journal:  Pathog Dis       Date:  2013-01-29       Impact factor: 3.166

4.  Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey.

Authors:  Murat Erkut; Doğan Yusuf Uzun; Neşe Kaklıkkaya; Sami Fidan; Yaşar Yoğun; Arif Mansur Coşar; Esma Akyıldız; Murat Topbaş; Orhan Özgür; Mehmet Arslan
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

Review 5.  Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.

Authors:  Alicia C Marin; Olga P Nyssen; Adrian G McNicholl; Javier P Gisbert
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

6.  Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.

Authors:  Javier P Gisbert; Jesús Barrio; Inés Modolell; Javier Molina-Infante; Angeles Perez Aisa; Manuel Castro-Fernández; Luis Rodrigo; Angel Cosme; Jose Luis Gisbert; Miguel Fernández-Bermejo; Santiago Marcos; Alicia C Marín; Adrián G McNicholl
Journal:  Dig Dis Sci       Date:  2014-09-19       Impact factor: 3.199

7.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

Review 8.  Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.

Authors:  Simona Di Caro; Lucia Fini; Yayha Daoud; Fabio Grizzi; Antonio Gasbarrini; Antonino De Lorenzo; Laura Di Renzo; Sara McCartney; Stuart Bloom
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

9.  Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection.

Authors:  Giuliana Sereni; Francesco Azzolini; Lorenzo Camellini; Debora Formisano; Francesco Decembrino; Veronica Iori; Cristiana Tioli; Maurizio Cavina; Francesco Di Mario; Giuliano Bedogni; Romano Sassatelli
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

Review 10.  Fluoroquinolone-based protocols for eradication of Helicobacter pylori.

Authors:  Antonio Rispo; Pietro Capone; Fabiana Castiglione; Luigi Pasquale; Matilde Rea; Nicola Caporaso
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.